TY - JOUR
T1 - Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa
AU - Morris, Jerry L.
AU - Hutton, J. Thomas
AU - Roman, Gustavo C.
AU - Imke, Susan C.
AU - Elias, Jeffrey W.
PY - 1988/1/1
Y1 - 1988/1/1
N2 - Controlled-release carbidopa/levodopa 50/200 (SINEMET CR) and standard carbidopa/levodopa (SINEMET 25/100) were compared in a double-blind, six-month, crossover study involving 21 patients with chronic Parkinson's disease and motor response fluctuations. Daily dosage frequency was significantly reduced with SINEMET CR compared with SINEMET 25/100, while the daily amount of levodopa required with SINEMET CR was significantly greater. No significant differences in disability ratings, motor response fluctuations, or safety were detected during double-blind conditions. In the open-label, dose-finding phase of the study, SINEMET CR was superior to standard SINEMET 25/100 in patient ratings of percent 'on' time (good motor function), clinical assessments of motor function, and activities of daily living. This finding resulted from a depreciation of the value of the 'old drug' rather than an overestimation of the value of the experimental drug. This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR.
AB - Controlled-release carbidopa/levodopa 50/200 (SINEMET CR) and standard carbidopa/levodopa (SINEMET 25/100) were compared in a double-blind, six-month, crossover study involving 21 patients with chronic Parkinson's disease and motor response fluctuations. Daily dosage frequency was significantly reduced with SINEMET CR compared with SINEMET 25/100, while the daily amount of levodopa required with SINEMET CR was significantly greater. No significant differences in disability ratings, motor response fluctuations, or safety were detected during double-blind conditions. In the open-label, dose-finding phase of the study, SINEMET CR was superior to standard SINEMET 25/100 in patient ratings of percent 'on' time (good motor function), clinical assessments of motor function, and activities of daily living. This finding resulted from a depreciation of the value of the 'old drug' rather than an overestimation of the value of the experimental drug. This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR.
UR - http://www.scopus.com/inward/record.url?scp=0023807258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023807258&partnerID=8YFLogxK
U2 - 10.1001/archneur.1988.00520320047014
DO - 10.1001/archneur.1988.00520320047014
M3 - Article
C2 - 3395259
AN - SCOPUS:0023807258
SN - 0003-9942
VL - 45
SP - 861
EP - 864
JO - Archives of neurology
JF - Archives of neurology
IS - 8
ER -